Solarea Bio Announces the Beta Launch of Bondia™, a Novel Daily Medical Food Helping Menopausal Women Manage Bone Loss

The complete beta launch experience, known as the Beta Complete Journey, includes a baseline total body DEXA scan, a year of Bondia™ capsules, and access to an accompanying mobile app.

May 08 2024

The NIH/National Institute on Aging has awarded a R01 $3 million grant to study the impact of a medical food developed by Solarea Bio

Hebrew SeniorLife, United States Department of Agriculture (USDA) Human Nutrition Research Center on Aging (HNRCA) at Tufts University, Maine Medical Center Research Institute, and Solarea Bio are grant recipients

Aug 25 2023

Solarea Bio Announces First Close of Series B Financing Round

Solarea Bio announced today a first closing of $15m in a Series B financing led by S2G Ventures with continued participation of Bold Capital Partners, Viking Global Investors, and GG 1978 SICAF SIF.

May 08 2023

Solarea Bio Investigators Receive National Academy of Medicine Healthy Longevity 2022 Quickfire Challenge Award

Work focuses on studying the mycobiome as a novel class of probiotics for the dietary management of inflammation associated with aging.

Sep 29 2022

Solarea first peer-review publication reveals green olives and other fruits and vegetables have vast microbial diversity with the potential to deliver probiotic functionality

Solarea Bio announces its first scientific publication of some of their core research in Scientific Reports, a Nature Portfolio journal. This pilot study describes the microbial diversity known as the “Edible Plant Microbiota” in four commonly consumed items.

Dec 15 2021

Solarea Bio Teams up with Hebrew SeniorLife Investigators on a Newly Awarded U.S. National Academy of Medicine Catalyst Grant

Solarea Bio and leading researchers at Harvard Medical School affiliated Hebrew SeniorLife, New England’s largest nonprofit provider of senior health care and living communities, are co-investigators on a competitive research grant from the U.S. National Academy of Medicine’s …

Nov 04 2021

Solarea Bio Announces Licensing Agreement with ADM

Solarea Bio, a biotech company based in Cambridge, MA that is developing microbial-based solutions to aid human health, today announced it has signed a technology licensing agreement with global nutrition leader ADM.

Oct 19 2021

Solarea Bio rounds out management team to gear up for commercialization of first product

Solarea Bio, a company launching microbiome products to combat inflammatory conditions and improve the lives of afflicted individuals, rounds out their management team with strong startup commercialization experience as they welcome Dr. David Easson, Chief Manufacturing Officer and …

Oct 07 2021

Solarea Bio Announces Series A Financing

Solarea Bio announced today it has raised $11.2M in a Series A financing led by S2G Ventures and Bold Capital Partners, along with continued investment from Viking Global and additional investment from the Gisev Family Office as a syndicate …

Oct 19 2020

Welcome Solarea Bio: Innovators Unlocking the Power of Microbes to Improve Human Health

S2G’s investment into Solarea provides an opportunity for S2G to support the next wave of functional foods. S2G’s led Solarea’s Series A fundraise with Bold Capital Partners, along with continued investment from Viking Global Investors and the Gisev …

Oct 19 2020